Trial Profile

Randomized, Phase II Trial to Evaluate the Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy Compared to Capecitabine Monotherapy for Triple Receptor-Negative Breast Cancer With Residual Invasive Cancer After Neoadjuvant Chemotherapy.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Capecitabine
Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms MIRINAE trial

23 Apr 2026 Planned End Date changed from 31 Jan 2027 to 31 Dec 2027.
23 Apr 2026 Planned primary completion date changed from 31 Jan 2024 to 31 Dec 2026.
07 Nov 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com